Treatment of the chronic myeloid leukemia by Hydrea in the Ho Chi Minh center for hematology and blood transfusion

ABSTRACT

88 patients with the chronic myeloid leukemia treated with Hydrea during 1/1999 - 12/2000. Most of them admitted to the center for hematology and blood transfusion in the conditions of very high leukocytosis and acute mortality risk due to cerebrovascular obstruction. Patients indicated by high dose of Hydrea in average duration of treatment of 6.5 (1.8 days. The treatment with Hydrea demonstrated that the survival duration of patients was lasted. The drug had fewer side effects. The treatment was not expensive. This is suitable for economic conditions of patients in Vietnam.